Identification of a novel heterozygous DYSF variant in a large family with a dominantly-inherited dysferlinopathy

Chiara Folland, Russell Johnsen, Adriana Botero Gomez, Daniel Trajanoski, Mark R. Davis, Ursula Moore, Volker Straub, Rita Barresi, Michela Guglieri, Hannah Hayhurst, Andrew M. Schaefer, Nigel G. Laing, Philipa J. Lamont, Gianina Ravenscroft

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Aims Dysferlinopathy is an autosomal recessive muscular dystrophy, caused by bi-allelic variants in the gene encoding dysferlin (DYSF). Onset typically occurs in the second to third decade and is characterised by slowly progressive skeletal muscle weakness and atrophy of the proximal and/or distal muscles of the four limbs. There are rare cases of symptomatic DYSF variant carriers. Here, we report a large family with a dominantly inherited hyperCKaemia and late-onset muscular dystrophy. Methods and Results Genetic analysis identified a co-segregating novel DYSF variant [NM_003494.4:c.6207del p.(Tyr2070Metfs*4)]. No secondary variants in DYSF or other dystrophy-related genes were identified on whole genome sequencing and analysis of the proband's DNA. Skeletal muscle involvement was milder and later onset than typical dysferlinopathy presentations; these clinical signs manifested in four individuals, all between the fourth and sixth decades of life. All individuals heterozygous for the c.6207del variant had hyperCKaemia. Histological analysis of skeletal muscle biopsies across three generations showed clear dystrophic signs, including inflammatory infiltrates, regenerating myofibres, increased variability in myofibre size and internal nuclei. Muscle magnetic resonance imaging revealed fatty replacement of muscle in two individuals. Western blot and immunohistochemical analysis of muscle biopsy demonstrated consistent reduction of dysferlin staining. Allele-specific quantitative PCR analysis of DYSF mRNA from patient muscle found that the variant, localised to the extreme C-terminus of dysferlin, does not activate post-transcriptional mRNA decay. Conclusions We propose that this inheritance pattern may be underappreciated and that other late-onset muscular dystrophy cases with mono-allelic DYSF variants, particularly C-terminal premature truncation variants, may represent dominant forms of disease.
Original languageEnglish
Article numbere12846
Number of pages10
JournalNeuropathology and Applied Neurobiology
Issue number7
Early online date20 Aug 2022
Publication statusPublished - Dec 2022


Dive into the research topics of 'Identification of a novel heterozygous DYSF variant in a large family with a dominantly-inherited dysferlinopathy'. Together they form a unique fingerprint.

Cite this